SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

direclidine

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 3
Time to market
If Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.
Why 6/10
The next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Since the readout is more than ~6 months out and Neurocrine is a multi-product company with INGREZZA generating over $1.1B/quarter in revenue, direclidine is a major pipeline asset but not a single-asset binary, justifying a score of 6.
Actionable Insight NEUTRAL

The next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.

Price Chart

Loading chart...

Executive Summary

Direclidine (NBI-1117568, HTL-0016878) is an investigational oral, selective M4 muscarinic receptor agonist being developed by Neurocrine Biosciences (NBIX) for schizophrenia, with a secondary Phase 2 program in bipolar I disorder. It is the first selective M4 orthosteric agonist to reach Phase 3 for schizophrenia. Positive Phase 2 data (August 2024) showed a statistically significant 7.5-point PANSS improvement at the 20 mg dose. A multi-study Phase 3 registrational program began in August 2025, with topline data expected in 2027. The drug competes in the emerging muscarinic agonist class against Bristol Myers Squibb's already-approved Cobenfy (KarXT). Neurocrine is a well-capitalized company with its marketed product INGREZZA generating over $1.1B in quarterly revenue, meaning direclidine is a major pipeline catalyst but not a make-or-break binary for the company.

How It Works

Direclidine is a selective activator (agonist) of the M4 muscarinic receptor, a type of docking station on brain cells that responds to the neurotransmitter acetylcholine. By activating M4 receptors, the drug indirectly calms overactive dopamine signaling in brain regions linked to psychosis, without directly blocking dopamine receptors the way most older antipsychotics do. This mechanism is intended to treat schizophrenia symptoms with a potentially different side-effect profile than standard antipsychotics.

Trial Status

Direclidine is in a multi-study Phase 3 registrational program for schizophrenia initiated in August 2025. Multiple trials are recruiting: an inpatient acute exacerbation study (NCT07105098, primary completion Nov 2027), a relapse prevention study (NCT07227818, recently expanded to 25 sites), and a long-term safety study (NCT07114874). A Phase 2 study for bipolar I disorder (NCT07288320) is also recruiting. Topline Phase 3 data for schizophrenia is expected in 2027.

The Two-Sided Case

▲ Bull Case4
Direclidine is a selective M4 orthosteric agonist, a differentiated mechanism from Cobenfy (which combines M1/M4 agonism with a peripheral blocker). If direclidine shows a cleaner side-effect profile or once-daily dosing advantage, it could carve out a meaningful share of the large schizophrenia market.
Phase 2 data showed a statistically significant 7.5-point PANSS improvement at the 20 mg dose (p=0.011, effect size 0.61) with generally good tolerability, providing a solid foundation for the Phase 3 registrational program.
Neurocrine is a well-capitalized company with INGREZZA generating over $1.1B in quarterly revenue, giving it the resources to fully commercialize direclidine without partnership dependence.
The muscarinic agonist class represents the first new mechanism of action for schizophrenia in decades, and direclidine is also being explored in bipolar I disorder (Phase 2), expanding its addressable market.
▼ Bear Case4
Direclidine faces a first-mover disadvantage: Bristol Myers Squibb's Cobenfy (KarXT, xanomeline/trospium) was FDA-approved for schizophrenia in September 2024 and is already on the market, establishing the muscarinic agonist class and potentially capturing prescriber mindshare before direclidine can reach Phase 3 readout.
Phase 3 trials in schizophrenia are notoriously high-risk; the Phase 2 study showed statistical significance only at the 20 mg dose (not at higher doses), raising questions about the therapeutic window and dose-response curve.
Topline data from the ongoing Phase 3 program is not expected until 2027 at the earliest, and some trials may read out as late as 2028, meaning no near-term binary catalyst and a long wait for investors.
Neurocrine's stock already carries a strong buy consensus and a mean price target implying ~42% upside, suggesting much of the direclidine optimism may already be priced in.

Upcoming Catalysts

  • Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (specific quarter not yet guided)
  • Phase 2 topline data for direclidine in bipolar I disorder (mania) - timeline not yet specified

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 prnewswire.com3 fool.com4 biospace.com5 prnewswire.com6 adisinsight.springer.com7 adisinsight.springer.com8 hcplive.com9 cnspulse.com10 cnspulse.com11 neurocrine.com12 synapse.patsnap.com